EUVIMEDEUVIMED entdecken
Open Access

The FAP × CD3 bispecific antibody OMTX305 induces T cell–mediated antitumor effects in patient-derived ex vivo models of solid tumors

Julia Thiel iD, Jan A Schlegel iD, Chunguang Liang iD, Thomas E Mürdter iD, Adrian Kneer, Sascha Dreher, Annelie Schäfer iD, Oliver Seifert iD, Lennart Kühl iD, Gerhard Preissler, Laureano Simon, Myriam Fabre und 8 weitere

Science Advances · 11.09.2026 · 12 (37)

DOI: 10.1126/sciadv.aee2124 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, erschienen am 11.09.2026. Verfasst von Julia Thiel und 19 weiteren Autor:innen. Beteiligte Einrichtung: Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology and University of Tübingen, 70376 Stuttgart, Germany. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Gelatinases, T-Lymphocytes, CD3 Complex. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Berthold Leibinger Stiftung, Robert Bosch Stiftung, Deutsche Forschungsgemeinschaft.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Within solid tumors, stromal barriers and immune exclusion limit the success of immunotherapies. Thus, novel therapeutic approaches are required to remodel the tumor-supportive microenvironment and enhance therapeutic responses. We developed a bispecific, trivalent Fab-eIg T cell engager (OMTX305) targeting fibroblast activation protein (FAP), a marker of tumor-promoting cancer-associated fibroblasts. The translational potential of OMTX305 was investigated in 2D and 3D patient-derived preclinical models, with a focus on precision-cut tumor slices (PCTSs) of lung and ovarian cancer cocultured with autologous PBMCs. By combining spatial biology with cytokine and transcriptomic analysis, we show that OMTX305 treatment eliminated FAP-expressing fibroblasts, induced interferon responses and extracellular matrix remodeling, ultimately triggering bystander killing of adjacent tumor cells. Distinct immune phenotypes and PD-L1 expression patterns appeared to be associated with differential treatment responses, suggesting their potential as biomarkers for patient stratification. Our findings highlight the clinical potential of targeting stromal elements as a cancer therapy and establish PCTS as a powerful preclinical platform for personalized immunotherapy assessment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, BispecificGelatinasesT-LymphocytesCD3 ComplexMembrane ProteinsSerine EndopeptidasesNeoplasmsHumansFibroblast Activation Protein AlphaEndopeptidasesTumor MicroenvironmentFemaleOvarian NeoplasmsImmunotherapyCoculture TechniquesCell Line, TumorAnimals

Substanzen

Antibodies, BispecificFibroblast Activation Protein AlphaGelatinasesCD3 ComplexMembrane ProteinsEndopeptidasesSerine Endopeptidases

Autor:innen und Institutionen

  • Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology and University of Tübingen, 70376 Stuttgart, Germany.
  • Institute of Immunology, Jena University Hospital, Friedrich-Schiller-University, 07743 Jena, Germany.
  • Comprehensive Cancer Center Central Germany (CCCCG), Jena University Hospital, 07743 Jena, Germany.
  • Department of Bioinformatics, Biocenter Am Hubland, University of Würzburg, 97074 Würzburg, Germany.
  • Cluster of Excellence iFIT (EXC 2180) "Image-guided and Functionally Instructed Tumor Therapies", University of Tübingen, Tübingen, Germany.
  • Department of Gynecology and Obstetrics, Robert Bosch Hospital, 70376 Stuttgart, Germany.

ORCID-Profile: Julia Thiel, Jan A Schlegel, Chunguang Liang, Thomas E Mürdter, Annelie Schäfer, Oliver Seifert, Lennart Kühl, Isabel Egaña, Katrin S Kurz, Roland E Kontermann, Walter E Aulitzky, Matthias Schwab, Monilola A Olayioye, Meng Dong

Förderung

  • Berthold Leibinger Stiftung
  • Robert Bosch Stiftung
  • Deutsche Forschungsgemeinschaft
  • Ministerium für Wissenschaft, Forschung und Kunst Baden-Württemberg
  • Bundesministerium für Forschung und Technologie

Zitieren

APA

Thiel, J., Schlegel, J. A., Liang, C., Mürdter, T. E., Kneer, A., Dreher, S., Schäfer, A., Seifert, O., Kühl, L., Preissler, G., Simon, L., Fabre, M., Egaña, I., Kurz, K. S., Ott, G., Kontermann, R. E., Aulitzky, W. E., Schwab, M., Olayioye, M. A., & Dong, M. (2026). The FAP × CD3 bispecific antibody OMTX305 induces T cell–mediated antitumor effects in patient-derived ex vivo models of solid tumors. Science Advances, 12(37). https://doi.org/10.1126/sciadv.aee2124

Vancouver

Thiel J, Schlegel JA, Liang C, Mürdter TE, Kneer A, Dreher S, et al. The FAP × CD3 bispecific antibody OMTX305 induces T cell–mediated antitumor effects in patient-derived ex vivo models of solid tumors. Science Advances. 2026;12(37). doi:10.1126/sciadv.aee2124

BibTeX
@article{Thiel2026,
  author = {Thiel, Julia and Schlegel, Jan A and Liang, Chunguang and Mürdter, Thomas E and Kneer, Adrian and Dreher, Sascha and Schäfer, Annelie and Seifert, Oliver and Kühl, Lennart and Preissler, Gerhard and Simon, Laureano and Fabre, Myriam and Egaña, Isabel and Kurz, Katrin S and Ott, German and Kontermann, Roland E and Aulitzky, Walter E and Schwab, Matthias and Olayioye, Monilola A and Dong, Meng},
  title = {The FAP × CD3 bispecific antibody OMTX305 induces T cell–mediated antitumor effects in patient-derived ex vivo models of solid tumors},
  journal = {Science Advances},
  year = {2026},
  volume = {12},
  number = {37},
  doi = {10.1126/sciadv.aee2124}
}
Kostenlos starten →